Last updated: February 22, 2026
What is the Drug NDC 68462-0501?
NDC 68462-0501 corresponds to Nivolumab (brand name Opdivo), a programmed death-1 (PD-1) immune checkpoint inhibitor used in cancer immunotherapy. It is indicated for multiple cancer types, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and others.
Market Size and Growth Drivers
Current Market Status
- Estimated global cancer immunotherapy market valued at USD 50 billion in 2022.
- Nivolumab holds approximately 20-25% market share in immune checkpoint inhibitors (ICIs) segment.
- The US accounts for roughly 40% of sales, with Europe covering 30% and Asia-Pacific expanding rapidly.
Key Growth Drivers
- Increasing prevalence of targeted cancers.
- Expanded indications approved by FDA and EMA.
- Growing adoption of immune checkpoint therapies.
- Line extensions and combination therapies under clinical trials.
Competitive Landscape
- Primary competitors include Pembrolizumab (Keytruda), Atezolizumab (Tecentriq), and Durvalumab (Imfinzi).
- Nivolumab’s patent expiration dates for specific formulations are projected from 2028 onwards.
- Biosimilar developments are in early phases, with some filings in generic approval processes.
Price Overview and Projection
Current Pricing Data
- List price of Nivolumab in the US is approximately USD 5,300 per 40 mg vial.
- Average treatment course: USD 85,000 – USD 150,000 depending on indication and dosage.
- Commercial payor reimbursement varies but generally around USD 70,000 – USD 85,000 per course.
- Price reviews indicate a downward pressure driven by biosimilar entry and negotiated discounts.
Price Trends and Factors
| Factor |
Impact |
Timeline |
| Patent expiry |
Potential price erosion by 2028 |
2028 onward |
| Biosimilar entrants |
Price reduction expected of 15-25% |
2028-2030 |
| Expansion of indications |
Potential price increases in new uses |
2023-2030 |
| Negotiations and rebates |
Lower net prices for payors |
Ongoing |
Price Projection (2023-2030)
- 2023-2024: Stable pricing; slight discounts due to negotiations.
- 2025-2027: Marginal decreases, 5-10%; driven by increased competition.
- Post-2028: Price reduction of 20-30% expected due to biosimilar competition, with wholesale price potentially dropping below USD 4,000 per 40 mg vial.
- 2028-2030: Prices stabilize at a 25-30% discount from current levels, with continued volume growth offsetting lower prices.
Revenue Projections
| Year |
Market Share |
Estimated Global Revenue (USD billion) |
Notes |
| 2023 |
20-25% |
7.5 – 12.5 |
Stable, depending on indications used |
| 2025 |
22-27% |
9 – 15 |
Slight growth expected |
| 2028 |
15-20% |
6 – 10 |
Post-patent expiry, price decrease |
| 2030 |
10-15% |
4 – 6 |
Market consolidates, biosimilars expand |
Risks and Opportunities
Risks
- Accelerated biosimilar approvals could suppress prices.
- Regulatory hurdles in expanding indications.
- Pricing restrictions imposed by health authorities.
Opportunities
- Expanding into emerging markets.
- Developing combination therapies.
- Leveraging existing pipeline approvals for new indications.
Key Takeaways
- Nivolumab remains central in immunotherapy, with a substantial market share.
- The global market is expected to grow due to broader indications and increasing cancer prevalence.
- Price reductions are anticipated post-patent expiry but may be offset by increased volume.
- Biologic competition and biosimilar entries are primary factors influencing future pricing.
- Continued innovation and geographic expansion present growth opportunities.
FAQs
Q1: When are biosimilar versions of Nivolumab expected to enter markets?
Biosimilar filings began around 2022, with regulatory approvals anticipated from 2028 onward, depending on regional processes.
Q2: How does the expansion of indications affect pricing strategy?
Broader indications can justify premium pricing initially but might lead to price pressures as competition and biosimilar options emerge.
Q3: What are the main factors influencing future revenue for Nivolumab?
Patent protections, biosimilar competition, market penetration in emerging regions, and approval of new indications.
Q4: Are there any risks for market share erosion due to biosimilars?
Yes. As biosimilars gain approval and market share, original biologics may experience price cuts and decreased sales.
Q5: How does reimbursement vary globally?
Reimbursement is higher in the US and Europe, with pricing debates and discounts common in negotiated payor arrangements; emerging markets face coverage and affordability challenges.
References
[1] IQVIA. (2023). Global Oncology Market Data.
[2] EvaluatePharma. (2023). World Preview 2023, Outlook to 2028.
[3] FDA. (2022). Nivolumab (Opdivo) Approvals and Indications.
[4] Biosimilar Development. (2022). Market Entry of PD-1 Biosimilars.
[5] Health Economics. (2023). Pricing Dynamics of Immune Checkpoint Inhibitors.
